Yesterday, community oncology leaders flooded the Hill to meet with Congress and the administration to warn them of the impact the Medicare sequester’s increased cuts and extension will have on cancer care nationwide.
Yesterday, community oncology leaders flooded the Hill to meet with Congress and the administration to warn them of the impact the Medicare sequester’s increased cuts and extension will have on cancer care nationwide.
The emergency Community Oncology Alliance (COA) fly-in was prompted by the momentum of the tax bill in both the US House and Senate. The bill proposes to raise the current sequester from 2% to 4%, as well as extend cuts at the end of the 10-year budget window.
In 2013, CMS enacted a 2% sequester payment cut to Medicare. The cut was originally intended to be an incentive to design an alternative budget savings package. The cut, signed into law in August 2011, set up the US cancer care system for consolidation and increased costs to seniors, Medicare, and taxpayers, says COA.
Since the sequester was enacted, the effect on the cancer care community has been felt across the nation. According to COA’s 2016 Practice Impact Report:
“We had over a dozen oncology leaders on the Hill yesterday talking about the devastating impact that this would have…not only would it be devastating, but it would be irresponsible of Congress,” Ted Okon, MBA, COA’s executive director, told The Center for Biosimilars® in an interview. “Regardless of whether this tax bill passes, we’ve been arguing all year that CMS in the prior administration should not have applied the sequester to Part B Medicare drugs. We’re at the point now that we’ve been working with Congress and talking to the current administration, and it remains to be seen what we’ll do next if they don’t either legislatively fix this, or if they don’t stop it from a regulatory standpoint.”
Jeff Vacirca, MD, president of COA and CEO of New York Cancer Specialists, also had a strong message for lawmakers. “Our elected officials need to understand that this sequester may seem like funny money to them but it is a slow bleed closing cancer clinics and forcing them into the waiting arms of more expensive hospital systems—especially those profiting off 340B. Congress needs to understand that their doubling down on the sequester and constantly extending it will result in community oncology practices being forced to shut their doors, which will cause access issues for patients and increase treatment costs as cancer care shifts to expensive hospitals,” said Vacirca in a statement.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.